Surgical Innovations Group (SUN) Fair Value & Analysis
Healthcare · GB · Market cap 4.4M GBX
Fair value as of: Jun 26, 2026
From 7 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from £0.0100 to £0.0050 (−50.0%) since Jun 25, 2026.
Price vs Fair Value (12 months)
12‑month range £0.0045 – £0.0070 · the £0.0048 price screens below the £0.0050 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Surgical Innovations Group (SUN) currently trades at £0.0048, while our model-based Fair Value estimate is £0.0050 — implying the stock looks roughly 5.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Surgical Innovations Group generated revenue of £11.6M at a net margin of -7.7%. Revenue declined 5.4% year over year. It earns a return on equity of -11.1%. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Surgical Innovations Group plc, together with its subsidiaries, engages in the design, manufacture, and export of medical products for use in laparoscopic and robotic minimally invasive surgery in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. The company operates through three segments: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. It offers YelloPort Elite port access systems; YelloPort + Resposable port access systems; LogiCut, a disposable laparoscopic scissors; Logic, a reusable laparoscopic grasping forceps and dissectors; LogiFlex, a dual purpose, Resposable device for blunt dissection and gastric band retrieval; FastClamp, a reusable laparoscopic clamping system, designed to fixate a range of instrumentation in position during minimally invasive surgery; PretzelFlex, a pretzel shaped organ and tissue retractor, designed for use in minimally invasive surgery; and LogiTube, a calibration tubing for gastric pouch sizin…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Surgical Innovations Group reported revenue of £11.6M in FY2025 versus £9.1M in FY2021, a compound +6.2%/yr. Reported net income was −£895K in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Surgical Innovations Group (SUN) undervalued?
What is the fair value of SUN?
What is the quality score of SUN?
What is the revenue of Surgical Innovations Group (SUN)?
What is the net profit margin of SUN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.